

| Funder  | Project Title  | Funding     | Strategic Plan Objective | Institution   |
|---|--|-------------|--------------------------|---|
| Brain & Behavior Research Foundation            | Exploration of resting-state network dynamics in autism spectrum disorders   | \$0         | Q4.Other                 | Harvard University  |
| Autism Speaks                                   | A multi-site double-blind placebo-controlled trial of memantine vs. placebo in children with autism                    | \$0         | Q4.L.A                   | Holland Bloorview Kids Rehabilitation Hospital  |
| Health Resources and Services Administration    | Controlled trial of sertraline in young children with Fragile X Syndrome   | \$285,970   | Q4.L.A                   | University of California, Davis   |
| National Institutes of Health                   | 1/3-Atomoxetine placebo and parent training in autism  | \$269,976   | Q4.S.F                   | University of Pittsburgh  |
| National Institutes of Health                   | 2/3-Atomoxetine placebo and parent training in autism  | \$350,730   | Q4.S.F                   | The Ohio State University   |
| National Institutes of Health                   | ACE Network: Early pharmacotherapy guided by biomarkers in autism  | \$1,996,122 | Q4.S.F                   | Wayne State University  |
| Health Resources and Services Administration    | Predictors of effects of propranolol on language & connectivity in autism  | \$192,150   | Q4.S.F                   | University of Missouri  |
| Health Resources and Services Administration    | Autism Intervention Research Network on Physical Health (AIR-P network)  | \$2,079,996 | Q4.S.A                   | Massachusetts General Hospital  |
| Department of Defense - Autism Research Program | Metabolic signature of antipsychotics used in the treatment of autism  | \$0         | Q4.L.C                   | University of Cincinnati  |
| National Institutes of Health                   | 3/3-Atomoxetine placebo and parent training in autism  | \$263,639   | Q4.S.F                   | University of Rochester   |
| National Institutes of Health                   | Early pharmacotherapy guided by biomarkers in autism (supplement)  | \$260,000   | Q4.S.F                   | Wayne State University  |
| National Institutes of Health                   | ACE Center: Augmenting language interventions for ASD: A translational approach  | \$281,072   | Q4.L.A                   | University of California, Los Angeles   |
| Department of Defense - Autism Research Program | A randomized, controlled trial of intranasal oxytocin as an adjunct to behavioral therapy for autism spectrum disorder | \$0         | Q4.S.C                   | Massachusetts General Hospital  |
| Department of Defense - Autism Research Program | Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial             | \$0         | Q4.L.A                   | University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School |
| Department of Defense - Autism Research Program | Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial             | \$0         | Q4.L.A                   | University of Medicine & Dentistry of New Jersey                                      |
| Department of Defense - Autism Research Program | Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial             | \$0         | Q4.L.A                   | University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School |
| National Institutes of Health                   | Building a selective inhibitory control tone in autism: An rTMS study  | \$219,780   | Q4.Other                 | University of Louisville  |
| National Institutes of Health                   | Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)   | \$634,243   | Q4.S.F                   | Medical University of South Carolina  |
| National Institutes of Health                   | ACE Network: Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors (SOARS-B)                              | \$2,589,347 | Q4.L.A                   | University of North Carolina at Chapel Hill   |
| National Institutes of Health                   | New experimental medicine studies: Fast-Fail Trials in autism spectrum disorders                                       | \$115,889   | Q4.L.A                   | University of California, Los Angeles   |

| Funder  | Project Title  | Funding   | Strategic Plan Objective | Institution                                       |
|---|--|-----------|--------------------------|---|
| National Institutes of Health                   | Trial of a glutamate antagonist in the treatment of OCD and autistic disorders   | \$33,959  | Q4.L.A                   | National Institutes of Health                     |
| Autism Speaks                                   | Mirtazapine treatment of anxiety in children and adolescents with pervasive developmental disorders                          | \$94,242  | Q4.L.C                   | Indiana University                                |
| Simons Foundation                               | Treatment of children with ASD and epileptiform EEG with divalproex sodium   | \$68,088  | Q4.S.A                   | Boston Children's Hospital                        |
| Autism Speaks                                   | Association of cholinergic system dysfunction with autistic behavior in fragile X syndrome: Pharmacologic and imaging probes | \$92,469  | Q4.L.A                   | Stanford University                               |
| Brain & Behavior Research Foundation            | The use of non-invasive brain stimulation to improve social relating in autism spectrum disorders                            | \$0       | Q4.S.F                   | Monash University                                 |
| Simons Foundation                               | Evaluation of a melanocortin agonist to improve social cognition in ASD.   | \$74,675  | Q4.L.A                   | University of Sydney                              |
| Autism Research Institute                       | Metabolic factors affecting gamma synchrony  | \$25,000  | Q4.S.C                   | University of Louisville                          |
| National Institutes of Health                   | Pharmacotherapy of pervasive developmental disorders   | \$182,830 | Q4.L.C                   | Indiana University-Purdue University Indianapolis |
| Department of Defense - Autism Research Program | Intranasal oxytocin for the treatment of children and adolescents with autism spectrum disorders (ASD)                       | \$0       | Q4.S.C                   | Holland Bloorview Kids Rehabilitation Hospital    |
| Autism Speaks                                   | Randomized controlled trial of oxytocin treatment for social deficits in children with autism                                | \$50,600  | Q4.L.A                   | Stanford University                               |
| Autism Speaks                                   | Randomized phase 2 trial of RAD001 (an MTOR inhibitor) in patients with tuberous sclerosis complex                           | \$65,000  | Q4.L.A                   | Boston Children's Hospital                        |
| Health Resources and Services Administration    | Leadership Education in Neurodevelopmental Disabilities  | \$26,000  | Q4.Other                 | University of Pennsylvania                        |

